Skip directly to site content Skip directly to search


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Sexually Transmitted Diseases (STDs)


Section Navigation
			
			CDC Home


Facebook
        Twitter
        LinkedIn
        Syndicate





STD QCS Questions and Answers										Related Pages
										The questions contained on this web page were submitted by participants during the *Recommendations for Providing Quality STD Clinical Services Webinar*, which was hosted on January 28, 2020.
The *Recommendations for Providing Quality STD Clinical Services* (*STD QCS*) complement CDC’s *Sexually Transmitted Diseases Treatment Guidelines, 2015 (STD Treatment Guidelines)*. *STD QCS* provides guidance on clinical operations and the types of services that should or could be available for STD care. Therefore, the responses here primarily address *STD QCS*-related questions. For questions related to the *2015 STD Treatment Guidelines*, resources are provided.
		**On This Page**
			GeneralResourcesPreventionScreeningPartner ServicesLaboratoryTreatmentReferral to or Consultation with a SpecialistGeneral
***Question: When and how will the new treatment guidelines be released? What updates are expected?***
In 2020, CDC expects to publish updated *STI Treatment Guidelines* based on the latest available science. After publication, the guidelines will be available on CDC’s STD website.  For notification when the guidelines are released, sign up for the Morbidity and Mortality Weekly Report (MMWR).

***Question: What is considered timely detection and treatment.  Is there an actual time frame to attempt to achieve?***
In general, *timely detection* means following screening guidance, offering partner services and providing same-day onsite testing.  *Timely treatment* means reducing the interval between testing and return visits, same-day treatments and expedited partner therapy (EPT).  Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 outlines quality services relevant to timely detection and treatment that clinical settings providing STD care should or could have available such as screening, partner services, prevention, laboratory and treatment. Specific guidance regarding screening schedules, partner services management and EPT is available in the 2021 STI Treatment Guidelines.
Resources
***Question: Where can I go for resources about caring for adolescents?***
CDC offers the following resources on caring for adolescents:
CDC Division of Adolescent and School Health
https://www.cdc.gov/healthyyouth/index.htm
https://www.cdc.gov/healthyyouth/resources.htmCDC Division of STD Prevention
https://www.cdc.gov/std/default.htm
https://www.cdc.gov/std/life-stages-populations/adolescents-youngadults.htm
***Question: Where can I go for resources for low-resource clinics?***
The STD QCS implementation guide (expected to be released in 2020) can help clinics better identify resource gaps. The National Network of STD Clinical Prevention Training Centers (NNPTC) are CDC-funded regional training centers which work to build clinician skills, knowledge and experience to address and prevent STDs. In addition to technical assistance, the NNPTCs provide in-person trainings, webinars, expert consultation and free or low-cost Continuing Medical Education (CME) or Certified Nurse Educator (CNE) courses from the National STD Curriculum’s online modules and question bank.
CDC also funds the NNPTC STD Clinical Consultation Network (STDCCN) which provides treatment guidance for health care professionals and STD program staff.
CDC’s STD website has a number of free resources. The National Coalition for STD Directors provides free resources for health care providers and STD programs.

***Question: Where can I go for more STI resources for patients?***
CDC’s STD website has patient resources organized by disease:
https://www.cdc.gov/std/products/default.htm
https://www.cdc.gov/std/healthcomm/fact_sheets.htm
https://www.cdc.gov/std/general/default.htm
https://www.cdc.gov/std/prevention/default.htm******
***Question: Where can I find more information on Quality Family Planning services?***
The Quality Family Planning Services recommendations are available on CDC’s reproductive health website: https://www.cdc.gov/reproductivehealth/contraception/qfp.htm.
******
***Question: Where can I find resources on sexual history taking?***
Please see CDC’s Taking a Sexual History Guide. This 2015 guide is being updated.
Prevention
***Question: Why are hepatitis A virus (HAV) antibody testing and HAV vaccine for those that are negative not a recommendation for primary care clinics [human papilloma virus (HPV) and hepatitis B virus (HBV) are recommended but not HAV]?***
CDC developed these recommendations after consultation with a wide range of experts and stakeholders. CDC also reviewed existing national guidelines, recommendations and current practice in the U.S.
*STD QCS* recommends the following:
1) on-site hepatitis B vaccination *should* be available as a basic STD care service in primary care settings; 2) **on-site** hepatitis A vaccination ***could*** be available as a basic STD care service in primary care settings; 3) serologic tests for hepatitis A, B, and C ***should***be available through a clinical laboratory as basic STD care services.
Current guidance on hepatitis A screening and vaccination recommendations is available on CDC’s hepatitis website.
******
***Question: HPV still seems to be the most common STD/STI. Are there new recommendations on reducing this virus aside from the vaccine?***
*STD QCS* focuses on the optimal services that should or could be available to individuals seeking STD care in primary care or STD specialty clinical settings. You can find more information about prevention strategies in the HPV infection section of the *2021 STI Treatment Guidelines*. You can find more information in the HPV vaccine recommendations MMWR.
Screening
***Question: Does a person who has never been sexually active need to have blood drawn for syphilis?***
Sexual histories and risk assessments are foundational to providing quality STD care services. A sexual history helps clinicians identify those individuals at risk for STDs and determine the appropriate testing and treatment management.
*STD QCS* recommends that syphilis screening should be available in primary care settings providing STD care, as well as STD specialty settings. You can find screening recommendations for syphilis summarized on CDC’s STD website.
******
***Question: Is it recommended to routinely test for hepatitis B? If a client presents for STD screening, should a hepatitis B surface antigen (HBsAg) test be done if the client has completed the hepatitis B vaccine series?***
Hepatitis B screening and assessment should be available in primary care settings providing STD care and STD specialty settings. The *Viral Hepatitis chapter* of the *STI Treatment Guidelines* describes recommendations on HBV (under the sections on pre-exposure vaccination, pre-vaccination serologic testing, and post-vaccination serologic testing). You can find the screening recommendations summarized on CDC’s STD website.
******
***Question: What are the recommendations for HPV testing in men?***
You can find general information on HPV testing in the HPV and Men fact sheet on CDC’s STD website.
******
***Question: What is the best way to do rectal pap?***
*STD QCS* recommends that anal cancer screening and assessment could be available as a specialized STD care service. The anal cancer section of the*STI Treatment Guidelines* includes information regarding screening and assessment.  Additional resources are available at the following links:
University of California, San Francisco: https://analcancerinfo.ucsf.edu/obtaining-specimen-anal-cytology
University of Washington, Seattle:  https://www.uwhealth.org/healthfacts/diagnostic-tests/7056.pdf
Northwest AETC https://www.youtube.com/watch?v=olNphfWcO1g
Partner Services
***Question: Thoughts on expedited partner therapy (EPT) for STDs? What is the recommendation for EPT for gonorrhea? Do you recommend EPT for trichomoniasis?***
EPT (where legal and where local or state jurisdictions do not prohibit by regulation) should be available in primary care settings providing STD care and STD specialty care settings as a partner service. EPT medications for gonorrhea and chlamydia should be available onsite as a specialized STD care service and should be available by prescription as a basic STD care service. Information on EPT, including recommendations for gonorrhea, chlamydia and trichomoniasis, is available in the *Clinical Prevention Guidance* chapter of the *2015 STD Treatment Guidelines.*
Laboratory
***Question: For post-treated chlamydia, how soon should full STI testing be done, 30 days or 3 months? How long does it take chlamydia, gonorrhea, and trichomonas to clear urine testing? Could you briefly state the testing time frame after exposure to STDs?***
Recommendations on retesting after treatment for chlamydia, gonorrhea or trichomoniasis are discussed in the follow-up section of the corresponding chapters in the *2021 STI Treatment Guidelines*.

***Question: Are you recommending gonorrhea culture in addition to nucleic acid amplification testing (NAAT)? In recommending “gonorrhea culture”, does that mean on-site Thayer Martin media and a candle jar or sending a gonorrhea culture to a lab?***
The *diagnostic considerations section*of the *2021 STI Treatment Guidelines* *Gonorrhea* chapter describes the various tests available for diagnosing gonorrhea.*STD QCS* outlines the quality laboratory tests that should or could be available at the time of the patient visit or in a clinical laboratory by clinical setting. Urogenital and extragenital NAAT testing for gonorrhea should be available at the time of the patient visit. Gonorrhea culture should be available through a clinical laboratory as a specialized STD care service. As basic STD care services, urogenital and extragenital NAAT testing for gonorrhea should be available through a clinical laboratory while gonorrhea culture could be through a clinical laboratory.
******
***Question: What are the thoughts on laboratories using automated rapid plasma reagin (RPR) tests (rather than automated treponemal tests) as the initial test for syphilis screening. Do you have a recommendation regarding Reverse Algorithm Testing for Syphilis?  In using the reverse algorithm for syphilis, do you recommend using******Treponema pallidum particle agglutination assay******(TPPA) as the final confirmatory?***
The syphilis diagnostic considerations section of the *2021 STI Treatment Guidelines* provides direction on syphilis serologic testing algorithms.  CDC syphilis laboratory guidelines are in development.
******
***Question: What is the status of rapid syphilis testing at the clinic level?  We’ve been told that current tests are not very accurate (not as sensitive nor selective as needed to be reliable).  Is there any particular test product you recommend? The challenge is that after rapid HIV testing, the patients often do not want to do the syphilis test because it’s a blood draw that’s sent out.***
In the United States, the Food and Drug Administration, or FDA, has approved one rapid syphilis test. While the testing is being used in both the clinic and outreach settings, it is important to understand its limitations before embarking on a rapid syphilis testing program. The syphilis diagnostic considerations section of the *2021 STI Treatment Guidelines* provides direction on syphilis serologic testing algorithms. CDC syphilis laboratory guidelines are in development.
******
***Question: On slide 39, a suggestion was made for trichomoniasis testing in clinic. We already test for females. Are you suggesting testing for males on demand?***
*STD QCS* focuses on quality laboratory tests that should or could be available at the time of the patient visit or in a clinical laboratory by clinical setting. Trichomoniasis screening guidance is outlined in the *2021 STI Treatment Guidelines.*
******
***Question: Please describe a situation where it is very useful to do Gram stain in the office when I have very good lab availability.***
Urethral Gram stain results can document the presence of urethritis and distinguish between gonococcal and nongonococcal urethritis in men.  The availability of this test at the point-of-care can help to direct appropriate antibiotic therapy and decrease unnecessary antibiotic exposure in men presenting with urethral symptoms.  *STD QCS* recommends that Gram stain could be available through a clinical laboratory as a basic STD care service. As a specialized STD care service, Gram stain should be available at the time of the patient visit. **
Treatment
***Question: Thoughts on same-day treatment while laboratories are pending and the issue of antibiotic resistance? Especially with gonorrhea on the Urgent Threat list for antimicrobial resistance? Have there been many cases of resistant chlamydia?***
The *Gonococcal Infections* chapter of the *2021 STI Treatment Guidelines* provides recommendations for gonorrhea regimens, including antimicrobial-resistant *N. gonorrhoeae.* Chlamydial resistance is thought to be rare though the issue is complicated by the lack of standardized testing methodology. To date, only a few cases of clinically significant chlamydia resistance in humans have been identified.
******
***Question: When a client has drug-resistant pharyngeal gonorrhea, is treated with ceftriaxone and azithromycin, returns to clinic for test-of-cure and states no sexual contact since treatment, does the client need to wait a few more weeks (thinking that gonorrhea takes longer to clear in throat) to******retest, or is this considered a treatment failure and client needs to be retreated?***
The *Gonococcal Infections* chapter of the *2021 STI Treatment Guidelines* provides guidance on managing  suspected cephalosporin treatment failure.  In addition, the NNPTC’s STDCCN is a resource for health care professionals and STD program staff to receive guidance on specific clinical case management.
******
***Question: If I don’t have ceftriaxone available, can I treat gonorrhea with 2 grams of******azithromycin?***
Azithromycin monotherapy is not a recommended or alternative regimen for the treatment of gonococcal infection. The *Gonococcal Infections* chapter of the *2021 STI Treatment Guidelines* provides recommendations for gonorrhea regimens. The NNPTC’s STDCCN is a resource for health care professionals and STD program staff to receive guidance on specific clinical case management.  Local STD programs also may be a resource for partnering on STD services.
******
***Question: Does the CDC recommend empirical treatment if a patient is symptomatic or only after a positive result?***
Sexual histories, risk assessments and physical examinations are foundational to providing quality STD care services. A sexual history and risk assessment allow clinicians to learn about an individual’s sexual practices, partners, prevention, and past sexual history and to determine risk factors.  A physical examination allows clinicians the opportunity to identify any signs of STDs, including those not identified by the patient. Information from a sexual history, risk assessment, and physical examination can help clinicians identify those at risk for STDs and determine appropriate testing and treatment management including presumptive treatment.

***Question: If an individual has RPR 1:2 but no confirmatory, should I treat without waiting for a confirmatory result?***
The *2021 STI Treatment Guidelines* describe diagnostic considerations for syphilis.
******
***Question: What is the suggestion for someone with recurrent monthly bacterial vaginosis (BV)?***
The*2021 STI Treatment Guidelines* outline recommendations on managing recurrent BV.
Mycoplasma genitalium (M. genitalium)/Ureaplasma: Testing & Treatment
***Question:******What are the recommendations for testing and treating M. genitalium and Ureaplasma? How should sex partners of individuals with M. genitalium be managed?***
The CDC does not recommend routine screening for *Ureaplasma* or *M. genitalium*.  The *2021 STI Treatment Guidelines* include guidance on managing *M. genitalium*, as well as sex partners.
Referral to or Consultation with a Specialist
***Question: Why is cephalosporin or IgE-mediated penicillin allergy considered a reason to refer to a specialist for complex chlamydia infections?***
The recommendation is intended to include referral of patients who are diagnosed with chlamydia-related pelvic inflammatory disease and have an antimicrobial allergy.
******
***Question: Is a patient who is living with HIV and has persistent elevation of syphilis titers after treatment considered a complex case needing referral to an infectious disease specialist?***
The *2021 STI Treatment Guidelines* outline recommendations on management and follow-up of syphilis in people with HIV. The NNPTC’s STDCCN is a resource for health care professionals and STD program staff to receive guidance on specific clinical case management. Local STD programs also may be a resource for partnering on STD services.
							
					
						Page last reviewed:  August 22, 2022					Content source: 	Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeSexually Transmitted Diseases (STDs)
Diseases & Related Conditionsplus icon
Bacterial Vaginosis (BV)
Chlamydia
Gonorrhea
Hepatitis
Herpes
HIV/AIDS & STDs
Human Papillomavirus (HPV)
*Mycoplasma genitalium (Mgen)*
Pelvic Inflammatory Disease (PID)
STDs & Infertility
STDs during Pregnancyplus icon
Fact Sheet
Detailed Fact Sheet
Statistics
Treatment and Care
Archive
STD Risk and Oral Sex
Syphilis
Trichomoniasis
Other STDsplus icon
Archive
Life Stages and Populationsplus icon
Adolescents and Young Adultsplus icon
Adolescents and Technology
Adolescents and STDs Fact Sheet
Gay, Bisexual and Other MSMplus icon
Gay Men & STDs Fact Sheet
Preventionplus icon
Guidance During Disruption of STD Clinical Services
Just Diagnosed?
Which STD Tests Should I Get?
STD Lowdown Infographic
Program Management & Evaluation Toolsplus icon
Effective Interventions
Gap Assessment Toolkit
Internet Partner Services Toolkit
Outbreak Response Resourcesplus icon
Congenital Syphilis HAN Template
Disseminated Gonococcal Infection HAN Template
Gonorrhea with Reduced Susceptibility HAN Template
LGV HAN Template
Practical Use of Program Evaluation
Program Operations Guidelines
S.P.A.C.E. Monkey
STD Informatics and Surveillance
Projects & Initiativesplus icon
EHE: Scaling Up HIV Prevention Services in STD Specialty Clinics
Gonococcal Isolate Surveillance Project (GISP)
Disease Interventionplus icon
Disease Intervention Training Centers
National Disease Intervention Specialists (DIS) Recognition Day
Resources
National Network of Prevention Training Centers (NNPTC)
STD PCHDplus icon
CDC DIS Workforce Development Funding
Guidance
STD Health Equityplus icon
Community Approaches to Reducing STDs
Sexual Health Cultural Competence Resources
Archive
STD Surveillance Network (SSuN)
Archive
Statisticsplus icon
STI Surveillance 2022
Gonococcal Isolate Surveillance Project Profiles
Syphilis Supplement
STI Prevalence, Incidence, and Cost Estimatesplus icon
At A Glance
Social Media Materials
Indian Health Service Reports
Social Media & Moreplus icon
The State of STIs Infographicplus icon
Customizable
HTML version
SDSB Contacts
Archive
Tools & Materialsplus icon
Brochuresplus icon
The Facts Brochures
Fact Sheets
Infographics
Provider Pocket Guides
Social Media Resources
Videos and Podcastsplus icon
Let’s Talk About Sexual Health
Safe in the City
Webinars
Widgets
Archive
Trainingplus icon
STD Prevention Courses
SASSI – SAS Training
STD Clinical Slidesplus icon
STD Clinical Slides
STD Picture Cardsplus icon
STD Picture Cards
Treatment and Screeningplus icon
Availability of STI Testing & Treatment Products
Duty to Warn
Expedited Partner Therapyplus icon
Gonorrhea Guidance
Legal Status of EPT
Legal/Policy Toolkit
Laboratory Information
Prenatal Syphilis Screening Laws
STD QCSplus icon
STD QCS Webinar Questions
STI Treatment Guidelines, 2021
A Guide to Taking a Sexual History
Additional Resources
Archive
About the Division of STD Preventionplus icon
STI Funding at Workplus icon
STI Prevention Success Stories
Success Bulletins
Strategic Plan 2022-2026
Fundingplus icon
Funding Archive
Archive For Healthcare Providers For Public Health Professionals Follow STD STD on Twitter
STD on Facebook


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue